Stay updated on AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial
Sign up to get notified when there's something new on the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page.

Latest updates to the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedSite version updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check46 days agoChange DetectedAdded a Show glossary option and updated non-critical metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), which do not alter the core study details or user actions.SummaryDifference0.2%

- Check61 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.0%

- Check82 days agoChange DetectedUpdated the study locations: new sites added across multiple US states (Georgia, Massachusetts, Michigan, New York, Pennsylvania, South Carolina, Texas) and international regions (New South Wales, Victoria, Ontario); some existing location entries were removed as part of a v3.3.3 update.SummaryDifference1.0%

Stay in the know with updates to AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AMG 820 and Pembrolizumab Combo in Solid Tumor Clinical Trial page.